Acquires 44.5% stake in Ascendio via in-kind contribution
경남제약
053950
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=643
Risk-adjusted indicator based on 643 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Acquired Shares: 16,233,418 Shares
- • Acquisition Amount: 13,100,368,326 KRW
- • Equity Ratio: 11.41%
- • Post-acquisition Ownership: 44.5%
- • Target Company 2025 Net Income: -13,803M KRW
AI Analysis Summary
KYUNG NAM PHARM.CO.,LTD. decided to acquire 16,233,418 shares (44.5% ownership) of its affiliate, Ascendio, for 13,100,368,326 KRW. This acquisition, representing 11.41% of the company's equity, will be executed through an in-kind contribution of land and buildings. The purpose is to expect investment returns. Ascendio, a film and broadcasting production company, reported a net loss of 13,803M KRW in 2025. The acquisition is scheduled for August 10, 2026. The transaction is a strategic investment in an affiliated company, with potential for long-term synergy, but the target company's recent financial performance shows losses.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.